Home | All trials

[RDF data]
Trial NCT00000663

Resource URI: http://static.linkedct.org/resource/trials/NCT00000663
PropertyValue
linkedct:brief_title A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection
linkedct:collaborator_agency <http://static.linkedct.org/resource/collabagency/3024>
linkedct:condition <http://static.linkedct.org/resource/condition/5486>
linkedct:criteria Inclusion Criteria Patients must have the following: - HIV-1 infection, or if less than 15 months old, born to mother with HIV-1 infection. - Legally qualified guardian with the ability to sign a written, informed consent form. - Willingness to abstain from all other experimental therapy for HIV-1 infection during the first 12 weeks of the study period. - Anticipated life expectancy of at least 3 months. Prior Medication: Allowed: - Prophylactic anti-Pneumocystis carinii pneumonia (PCP) or antifungal therapy. - Gamma globulin as prophylaxis for measles and varicella. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Past or present history of neurological abnormalities including withdrawal syndrome or seizures. - Past or present history of any serious active opportunistic infection including Pneumocystis carinii pneumonia (PCP). - Echocardiogram values > 2 standard deviations from normal. - Hematologic, renal, or hepatic insufficiency. Concurrent Medication: Excluded: - Zidovudine (AZT). - Intravenous gamma globulin (IVIG) except as prophylaxis for measles and varicella. - Cancer chemotherapy. - Corticosteroids. - Other known immunomodulatory agents. - Other experimental therapy not specifically allowed. Patients with the following are excluded: - Hematologic, renal, or hepatic insufficiency. - Past or present history of any serious active opportunistic infection. Prior Medication: Excluded for a minimum of 3 weeks prior to study entry: - Zidovudine (AZT). - Intravenous gamma globulin (IVIG). - Cancer chemotherapy. - Immunomodulatory agents. - Acyclovir and other experimental therapy. Risk Behavior: Excluded: - Patients born to substance abusing mothers (including alcohol) during the pregnancy.
linkedct:description CD4-IgG may be effective in blocking HIV transmission and spread, that is, CD4-IgG has antiviral effects. Studies done in adult patients with AIDS and AIDS related complex (ARC) have shown that rCD4 can be safely administered by intravenous bolus, intramuscular or subcutaneous injection. No serious or dose-limiting, drug-related toxicities have been observed to date. Patients receive one intravenous injection the first week, followed by a 6 day washout period and then intravenous injections on a twice weekly basis from week 2 to week 12. The dose per injection may vary. The study evaluates 2 groups: (1) Children 3 months to 5 years of age; (2) Infants 0-3 months of age.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 5 Years
linkedct:eligibility_minimum_age N/A
linkedct:enrollment 18 (xsd:int)
linkedct:firstreceived_date November 2, 1999
linkedct:id NCT00000663
rdfs:label Trial NCT00000663
linkedct:lastchanged_date June 23, 2005
linkedct:lead_sponsor_agency National Institute of Allergy and Infectious Diseases (NIAID)
linkedct:location <http://static.linkedct.org/resource/location/153890>
linkedct:location <http://static.linkedct.org/resource/location/154945>
linkedct:location <http://static.linkedct.org/resource/location/173658>
linkedct:location <http://static.linkedct.org/resource/location/192654>
linkedct:location <http://static.linkedct.org/resource/location/197348>
linkedct:location <http://static.linkedct.org/resource/location/202102>
linkedct:location <http://static.linkedct.org/resource/location/213402>
linkedct:nct_id NCT00000663
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection
linkedct:org_study_id ACTG 139
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/48256>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/60573>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000663>
linkedct:phase Phase 1
linkedct:reference <http://static.linkedct.org/resource/reference/3579>
linkedct:reference <http://static.linkedct.org/resource/reference/8518>
linkedct:secondary_id D0172g
linkedct:source National Institute of Allergy and Infectious Diseases (NIAID)
linkedct:study_design Treatment, Pharmacokinetics Study
linkedct:study_type Interventional
linkedct:summary To determine the safety profile, assess pharmacokinetic properties (blood levels), and obtain preliminary indication of the antiviral and immunologic effects of recombinant CD4 immunoglobulin G (CD4-IgG). CD4-IgG may be effective in blocking HIV transmission and spread, that is, CD4-IgG has antiviral effects. Studies done in adult patients with AIDS and AIDS related complex (ARC) have shown that rCD4 can be safely administered by intravenous bolus, intramuscular or subcutaneous injection. No serious or dose-limiting, drug-related toxicities have been observed to date.
rdf:type linkedct:trials
linkedct:verification_date October 1996